N(4)-Hydroxycytidine CAS 3258-02-4 EIDD-1931 NHC High Quality
Supply with High Purity and Stable Quality
Kemikari Zita: N (4)-Hydroxycytidine;EIDD-1931 (NHC)
CAS: 3258-02-4
Iyo inoshanda metabolite yeMolnupiravir, inovimbisa COVID-19 inhibitor
| Chemical Name | N(4)-Hydroxycytidine |
| Mashoko anoreva zvakafanana | EIDD-1931 (NHC);β-D-N4-Hydroxycytidine |
| Nhamba yeCAS | 3258-02-4 |
| Nhamba yeCAT | RF-PI309 |
| Stock Status | MuStock, Kugadzirwa Kunokwira Kusvika Makirogiramu |
| Molecular Formula | C9H13N3O6 |
| Molecular Weight | 259.22 |
| Melting Point | 169.0 ~ 172.0℃ |
| Solubility | Soluble kusvika 100 mM muDMSO uye kusvika 50 mM mumvura |
| Density | 1.93±0.1 g/cm3 |
| Brand | Ruifu Chemical |
| Item | Zvinotsanangurwa |
| Chitarisiko | Ichena kusvika kuOff-White Powder |
| NMR | Zvinoenderana NeChimiro |
| Kuchena / Analysis Method | > 98% (HPLC) |
| Kurasika paKuomesa | ≤1.0% |
| Kusachena Kumwechete | ≤0.50% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Iyo inoshanda metabolite yeMolnupiravir (EIDD-2801), COVID-19 inhibitor. |
Package: Bhodhoro, Aluminium foil bag, Cardboard dhiramu, 25kg/Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza, mwando uye tumbuyu.
N(4)-Hydroxycytidine (EIDD-1931, β-d-N4-hydroxycytidine, NHC, CAS 3258-02-4) metabolite inoshanda yeEIDD-2801, inovimbisa COVID-19 inhibitor.EIDD-1931 (NHC) ine yakafara spectrum antiviral chiitiko kurwisa akawanda coronavirus, kusanganisira SARS-CoV-2, MERS-CoV, SARS-CoV, uye inoenderana zoonotic boka 2b kana 2c Bat-CoVs ine avhareji IC50 ye0.15 μM, pamwe ne yakawedzera simba kurwisa coronavirus ine kuramba shanduko kune iyo nucleoside analog inhibitor remdesivir.Mune mbeva dzine utachiona neSARS-CoV kana MERS-CoV, zvose prophylactic uye kurapa kwekutonga kweMolnupiravir (EIDD-2801), an orally bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5'-isopropyl ester), yakagadziridzwa pulmonary function. , uye kuderedzwa kwehutachiona titer uye kurasikirwa kwehuremu hwemuviri.Kuderera kweMERS-CoV goho mu vitro uye mu vivo zvakabatanidzwa nekuwedzera shanduko mutation frequency muvhairasi asi kwete host cell RNA, ichitsigira nzira inouraya mutagenesis muCoV.Iyo potency yeNHC/EIDD-2801 ichipokana nemakoronavirus akawanda uye nemuromo bioavailability inosimbisa kugona kwayo kushanda senge inoshanda antiviral kurwisa SARS-CoV-2 nemamwe ramangwana zoonotic coronaviruses.
